These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26910383)

  • 1. Interferon Alpha-2a Therapy in Patients with Refractory Behçet Uveitis.
    Hasanreisoglu M; Cubuk MO; Ozdek S; Gurelik G; Aktas Z; Hasanreisoglu B
    Ocul Immunol Inflamm; 2017 Feb; 25(1):71-75. PubMed ID: 26910383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients.
    Lee JH; Lee CS; Lee SC
    BMC Ophthalmol; 2018 Feb; 18(1):52. PubMed ID: 29463220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments.
    Sobaci G; Erdem U; Durukan AH; Erdurman C; Bayer A; Köksal S; Karagul S; Bayraktar MZ
    Ophthalmology; 2010 Jul; 117(7):1430-5. PubMed ID: 20417563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of interferon alpha-2a therapy in patients with Behcet's disease.
    Yalçindağ FN; Uzun A
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
    Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
    Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Affecting Relapse and Remission in Behçet's Uveitis Treated with Interferon Alpha2a.
    Celiker H; Kazokoglu H; Direskeneli H
    J Ocul Pharmacol Ther; 2019; 35(1):58-65. PubMed ID: 30359208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
    Park JY; Chung YR; Lee K; Song JH; Lee ES
    Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.
    Aydinoglu-Candan Ö; Araz-Erşan B; Gul A; Badur S; Tugal-Tutkun I
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):457-65. PubMed ID: 25500983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exceptional case of full-thickness macular hole closure in a patient with Behçet disease.
    Uçar D; Atalay E; Özyazgan Y; Özkök A; Yıldırım Y
    Ocul Immunol Inflamm; 2014 Feb; 22(1):79-81. PubMed ID: 24063599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.
    Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S
    Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose interferon alfa-2a therapy in severe uveitis associated with Behçet disease.
    Onal S; Kazokoglu H; Direskeneli H; Yavuz S
    Am J Ophthalmol; 2009 Jun; 147(6):1109-10; author reply 1110. PubMed ID: 19463552
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
    Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
    Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional immunosuppressive therapy in severe Behcet's Uveitis: the switch rate to the biological agents.
    Celiker H; Kazokoglu H; Direskeneli H
    BMC Ophthalmol; 2018 Oct; 18(1):261. PubMed ID: 30290779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s.
    Cingu AK; Onal S; Urgancioglu M; Tugal-Tutkun I
    Ocul Immunol Inflamm; 2012 Dec; 20(6):423-8. PubMed ID: 23163330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of interferon-alfa therapy in patients with Behçet uveitis.
    Tugal-Tutkun I; Güney-Tefekli E; Urgancioglu M
    Graefes Arch Clin Exp Ophthalmol; 2006 Dec; 244(12):1692-5. PubMed ID: 16673135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Efficacy of Interferon in Severe Uveitis Associated with Behçet Disease.
    Diwo E; Gueudry J; Saadoun D; Weschler B; LeHoang P; Bodaghi B
    Ocul Immunol Inflamm; 2017 Feb; 25(1):76-84. PubMed ID: 27541620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF; Al-Hemidan AI
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Results of Interferon-Alpha Treatment in Behçet Uveitis.
    Eser-Ozturk H; Sullu Y
    Ocul Immunol Inflamm; 2020 Apr; 28(3):498-504. PubMed ID: 31161949
    [No Abstract]   [Full Text] [Related]  

  • 20. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients].
    Stübiger N; Kötter I; Deuter C; Zierhut M
    Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.